Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 357 (9271), 1870-5

Lessons From the Glitazones: A Story of Drug Development

Affiliations
Review

Lessons From the Glitazones: A Story of Drug Development

E A Gale. Lancet.

Abstract

Troglitazone, the first in the thiazolidinedione class of oral hypoglycaemic agents, was launched in the USA in March, 1997. It reached Europe later that year, only to be withdrawn within weeks on the grounds of liver toxicity. Meanwhile it went on to generate sales of over $2 billion in the USA, and caused at least 90 cases of liver failure (70 resulting in death or transplantation) before it was withdrawn in March, 2000. Rosiglitazone and pioglitazone reached the US market in 1999 as first-line agents to be used alone or in combination with other drugs, but in Europe the same dossiers were used one year later to apply for a limited licence as second-line agents restricted to oral combination therapy. How should we use the glitazones? And how did they achieve blockbuster status without any clear evidence of advantage over existing therapy?

Comment in

  • Lessons from the glitazones.
    Ramjiawan B, Mantsch HH. Ramjiawan B, et al. Lancet. 2001 Oct 13;358(9289):1274. doi: 10.1016/S0140-6736(01)06370-X. Lancet. 2001. PMID: 11675097 No abstract available.
  • Lessons from the glitazones.
    Saint Raymond A, Le Courtois P. Saint Raymond A, et al. Lancet. 2001 Oct 13;358(9289):1274. doi: 10.1016/s0140-6736(01)06369-3. Lancet. 2001. PMID: 11675098 No abstract available.

Similar articles

See all similar articles

Cited by 48 articles

See all "Cited by" articles

MeSH terms

LinkOut - more resources

Feedback